Blue Note Therapeutics

Blue Note Therapeutics was a prescription digital therapeutics company dedicated to improving mental health outcomes for cancer patients. The company focused on addressing cancer-related challenges such as anxiety and depression through clinically validated, FDA-cleared digital interventions. Its flagship product, attune™, was the first digital therapeutic program specifically designed to treat these symptoms. Attune was an on-demand mobile app that provided evidence-based therapies tailored for cancer patients. Headquartered in San Francisco, California, Blue Note Therapeutics combined scientific expertise and digital innovation to develop a pipeline of prescription digital therapeutics aimed at reducing cancer-related distress. The company engaged in research and development focused on nervous system diseases and cancer, with multiple products in various stages of development.

• Employees 5
• Founded 2018
• Annual Revenue $1500000
• Total Funding $46924996